Advanced cardiac life support or advanced cardiovascular life support (ACLS) refers to a set of clinical interventions for the urgent treatment of cardiac arrest, stroke and other life-threatening medical emergencies, as well as the knowledge and skills to deploy those interventions.
Advanced cardiac life support or advanced cardiovascular life support (ACLS) refers to a set of clinical interventions for the urgent treatment of cardiac arrest, stroke and other life-threatening medical emergencies, as well as the knowledge and skills to deploy those interventions.
Pharmacology is an important part of ACLS program. In ACLS Program,we are using many essential drugs for surviving cardiac arrest cases in Emergency department. We are introducing ACLS which is locally called ARC ( Advanced Resuscitation Course) started in Square Hospitals Ltd,Dhaka,Bangladesh. Hope it will help many health care provider to know the useful medication in case of CPR.
Advanced Cardiovascular Life Support (ACLS) is the pre-eminent resuscitation course for the recognition and intervention of cardiopulmonary arrest or other cardiovascular emergencies.
Pharmacology is an important part of ACLS program. In ACLS Program,we are using many essential drugs for surviving cardiac arrest cases in Emergency department. We are introducing ACLS which is locally called ARC ( Advanced Resuscitation Course) started in Square Hospitals Ltd,Dhaka,Bangladesh. Hope it will help many health care provider to know the useful medication in case of CPR.
Advanced Cardiovascular Life Support (ACLS) is the pre-eminent resuscitation course for the recognition and intervention of cardiopulmonary arrest or other cardiovascular emergencies.
Saludos! de parte del Ceipem (Centro de Entrenamiento e instrucción para profesionales en Emergencias Médicas), nuestra misión es brindar al profesional de la salud en un ambiente de simulación( Laboratorio de Simulación ), la oportunidad de adquirir habilidades y destrezas, desarrollar competencias individuales y/o grupales ante emergencias médicas, en los ámbitos pre e intra hospitalarios, contamos con el mejor Staff de profesionales para facilitar su aprendizaje. Cualquier información no dude en consultarnos, 0212 7314967/4063 /info@ceipem.org/ www.ceipem.org y si quieres ver fotos, videos y nuestras actividades ingresa por FACEBOOK en ceipem fundación y estarás en línea directa con nuestra comunidad de alumnos y docentes.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Welcome to Secret Tantric, London’s finest VIP Massage agency. Since we first opened our doors, we have provided the ultimate erotic massage experience to innumerable clients, each one searching for the very best sensual massage in London. We come by this reputation honestly with a dynamic team of the city’s most beautiful masseuses.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfEnterprise Wired
From navigating policy options to staying informed about industry trends, this comprehensive guide explores everything you need to know about the health insurance market.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
1. American Heart Association
ACLS Pre-Course Self Assessment
Dec., 2006
ECG Analysis
Name the following rhythms from the list below:
Normal Sinus Rhythm NSR Sinus Bradycardia
Sinus Tachycardia Atrial Flutter
Supraventricular Tachycardia SVT Atrial Fibrillation
Fine Ventricular Fibrillation Coarse Ventricular Fibrillation
Monomorphic VTach Polymorphic VTach (Torsades)
2nd
degree I Block 2nd
degree II Block
3rd
degree block Asystole
1.
2.
3.
4.
This pre-test is exactly the same as the pretest on the
ACLS Provider manual CD. This paper version can
be completed in place of the CD version if you wish.
2. Name the following rhythms from the list below:
Normal Sinus Rhythm NSR Sinus Bradycardia
Sinus Tachycardia Atrial Flutter
Supraventricular Tachycardia SVT Atrial Fibrillation
Fine Ventricular Fibrillation Coarse Ventricular Fibrillation
Monomorphic VTach Polymorphic VTach (Tordsades)
2nd
degree I Block 2nd
degree II Block
3rd
degree block Asystole
5.
6.
7.
8.
9.
3. Name the following rhythms from the list below:
Normal Sinus Rhythm NSR Sinus Bradycardia
Sinus Tachycardia Atrial Flutter
Supraventricular Tachycardia SVT Atrial Fibrillation
Fine Ventricular Fibrillation Coarse Ventricular Fibrillation
Monomorphic VTach Polymorphic VTach (Torsades)
2nd
degree I Block 2nd
degree II Block
3rd
degree block Asystole
10.
11.
12.
13.
14.
4. Name the following rhythms from the list below:
Normal Sinus Rhythm NSR Sinus Bradycardia
Sinus Tachycardia Atrial Flutter
Supraventricular Tachycardia SVT Atrial Fibrillation
Fine Ventricular Fibrillation Coarse Ventricular Fibrillation
Monomorphic VTach Polymorphic VTach (Torsades)
2nd
degree I Block 2nd
degree II Block
3rd
degree block Asystole
15.
16.
17.
18.
19.
20.
5. Pharmacology
21. Which of the following is most accurate regarding the administration of vasopressin during cardiac arrest?
a. Vasopressin is indicated for VF and pulseless VT prior to the delivery of the first shock
b. The correct dose of Vasopressin is 40 U administered IV or IO
c. Vasopressin is recommended instead of epinephrine for the treatment of asystole
d. Vasopressin can be administered twice during cardiac arrest
22. Your patient has been intubated. IV/IO access is not available. Which combination of drugs can be
administered by the endotracheal route of administration?
a. Amiodarone, lidocaine, epinephrine
b. Epinephrine, vasopressin, amiodarone
c. Lidocaine, epinephrine, vasopressin
d. Vasopressin, amiodarone, lidocaine
23. Which of the following statements about the use of magnesium in cardiac arrest is most accurate?
a. Magnesium is indicated for VF/pulseless VT associated with torsades de pointes
b. Magnesium is indicated for shock-refractory monomorphic VT
c. Magnesium is contraindicated in VT associated with a normal QT interval
d. Magnesium is indicated for VF refractory to shock and amiodarone or lidocaine.
24. A patient with a possible acute coronary syndrome has ongoing chest discomfort unresponsive to 3
sublingual nitroglycerine tablets. There are no contraindications and 4 mg of morphine sulfate was
administered. Shortly, BP falls to 88/60 and the patient complains of increased chest discomfort. You
would:
a. Give an additional 2 mg of morphine sulfate
b. Start dopamine at 2 ụg/kg per minute and titrate to BP 100 systolic.
c. Give nitroglycerin 0.4 mg sublingually
d. Give normal saline 250 mL to 500 mL fluid bolus
25. A patient has a rapid irregular wide-complex tachycardia. The ventricular rate is 138. He is asymptomatic
with a BP of 110/7-. He has a history of angina. Which of the following actions is recommended?
a. Give lidocaine 1-1.5 mg IV bolus
b. Immediate synchronized cardioversion
c. Seek expert consultation
d. Give adenosine 6 mg IV bolus
26. A 62 year-old man suddenly began to experience difficulty speaking and left-sided weakness. He is
brought to the ER. He meets initial criteria for fibrinolytic therapy and a CT scan of the brain is ordered.
Guidelines for antiplatelet and antothrombotic therapy are:
a. Administer heparin if CT scan is negative for hemorrhage
b. Give aspirin 160 mg and clopidogrel 75 mg orally
c. Administer aspirin 160-325 mg orally chewed, immediately
d. Do not give aspirin for at least 24 hours if tPA is administered
6. 27. A patient is in cardiac arrest. VFib has been refractory to an initial shock. Two attempts at peripheral IV
have been unsuccessful. The next recommended access route of administration for the delivery of drugs
during CPR is:
a. External jugular vein
b. Femoral vein
c. Intraosseous
d. Endotracheal
28. A patient with an ST-segment elevation MI has ongoing chest discomfort. Fibrinolytic therapy has been
ordered. Heparin 4000 U IV bolus was administered and a heparin infusion 100 U per hour is being
administered, and Aspirin was not taken by the patient because he had a history of gastritis treated 5 years
ago. Your next action is to:
a. Substitute clopidogrel 300 mg loading dose
b. Give aspirin 160 – 325 mg chewed, immediately
c. Give 75 mg enteric-coated aspirin only
d. Give 325 mg enteric-coated aspiring rectally
29. A patient with possible ACS and a bradycardia of 42/min has ongoing chest discomfort. What is the initial
dose of atropine?
a. Atropine 0.5 mg
b. Atropine 1.0 mg
c. Atropine 0.1 mg
d. Atropine 3 mg
30. A patient is in cardiac arrest. VFib has been refractory to an initial shock. Of the following, which drug
and dose should be administered first by IV/IO route?
a. Atropine 1 mg
b. Epinephrine 1 mg
c. Vasopressin 20 U
d. Sodium bicarbonate 50 mEq
31. A 35-year old woman has palpitations, lightheadedness, and a stable tachycardia. The monitor shows a
regular narrow-complex QRS at a rate of 180/min. Vagal maneuvers have not been effective in terminating
the rhythm. An IV has been established. What drug should be administered IV?
a. Epinephrine 2-10 ụg/kg per minute
b. Atropine 0.5 mg
c. Lidocaine 1 mg/kg
d. Adenosine 6 mg
32. A patient with a possible ST-segment elevation MI has ongoing chest discomfort. Which of the following
would be a contraindication for administration of nitrates?
a. HR of 90/min
b. BP > 180 systolic
c. Use of phosphodiesterase inhibitor within 12 hours
d. Left ventricular infarct with bilateral rales
7. 33. A patient has sinus bradycardia with a rate of 36/min. Atropine has been administered to a total dose of 3
mg. TCP has failed to capture. The patient is confused and BP is 100/60. Which of the following is now
indicated?
a. give additional 1mg Atropine
b. Give NS bolus 250 mL-500mL
c. Start dopamine 10-20 ụg/kg per minute
d. Start epinephrine 2-10 ụg/min
34. A patient is in pulseless VTach. Two shocks and one dose of epinephrine have been given. The next
drug/dose to anticipate to administer is:
a. Vasopressin 40U
b. Amiodarone 150 mg
c. Lidocaine 0.5 mg/kg
d. Epinephrine 3 mg
e. Amiodarone 300 mg
35. A patient is in refractory VFib and has received multiple appropriate defibrillations, epinephrine 1 mg IV
twice, and an initial dose of lidocaine IV. The patient is intubated. A second dose of lidocaine is now
called for. The recommended second dose of lidocaine is:
a. 0.5-0.75 mg/kg IV push
b. 2-3 mg/kg IV push
c. Give endotracheal dose 2-4 mg/kg
d. Start infusion 1-2 mg/min
e. 1 mg/kg IV push
36. You arrive on-scene with the Code Team. High-quality CPR is in progress. An AED has previously
advised “no shock indicated”. A rhythm now finds asystole. The next action you would take is to:
a. place a Combitube or Laryngeal Mask Airway (LMA)
b. Attempt intubation with minimal CPR interruption
c. Call for a pulse check
d. Place IV or IO access
37. Which of the following is most accurate regarding the administration of vasopressin during cardiac arrest?
a. Vasopressin is indicated for VF and pulseless VT prior to the delivery of the first shock
b. Vasopressin can be administered twice during cardiac arrest
c. Vasopressin is recommended instead of epinephrine for the treatment of asystole
d. The correct dose of Vasopressin is 40 U administered IV or IO
38. A patient is in cardiac arrest. High-quality chest compression are being given. The patient is intubated and
an IV has been established. The rhythm is asystole. The first drug/dose to administer is:
a. Atropine 0.5 mg IV or IO
b. Epinephrine 3 mg via ETT
c. Dopamine 2 to 20 ụg/kg per minute IV or IO
d. Atropine 1 mg IV or IO
e. Epinephrine 1 mg or Vasopressin 40 U IV or IO
8. 39. A 57 year-old woman has palpitations, chest discomfort and tachycardia. The monitor shows a regular
wide-complex QRS at a rate of 180.min. She becomes diaphoretic and BP is 80/60. The next action is to:
a. Obtain 12 lead ECG
b. Perform immediate synchronized cardioversion
c. Establish IV and give sedation for electrical cardioversion
d. Give amiodarone 300 mg IV push
40. A patient is in refractory VFib. High quality CPR is in progress and shocks have been given. One dose of
epinephrine was given after the second shock. An antiarrhythmia drug was given immediately after the
third shock. What drug should the team leader request to be prepared for administration?
a. Repeat the antiarrhythmic
b. Escalating dose epinephrine 3 mg
c. Second dose of epinephrine 1 mg
d. Sodium bicarbonate 50 mEq
41. A bradycardia rhythm IS treated when:
a. HR is < 60 with or without symptoms
b. BP < 100 systolic with out without symptoms
c. The patient has an MI on the 12-lead ECG
d. CP or shortness of breath is present
Practical Application
42.
You arrive on the scene to find CPR in progress. Nursing staff report that the patient was recovering from a
pulmonary embolism and suddenly collapsed. There is no pulse or spontaneous respirations. High-quality CPR
is in progress and effective ventilation is being provided with bag-mask. An IV has been initiated. You would
now:
a. order immediate endotracheal intubation
b. give epinephrine 1.0 mg IV
c. give atropine 1 mg IV
d. give atropine 0.5 mg IV
e. initiate transcutaneous pacing
9. 43
You are monitoring this patient after successful resuscitation. You note the above rhythm on the cardiac
monitor and document a rhythm strip for the patient’s chart. She has no complaints and blood pressure is
110/70 mm Hg. Now you would:
a. prepare for transcutaneous pacing (place pacing pads, do not pace yet)
b. give atropine 0.5 mg IV
c. start dopamine 2 to 10 ụg/kg per minute and titrate heart rate
d. give atropine 1 mg IV
e. administer sedation and begin immediate transcutaneous pacing at 80 beats/min
44.
Following initiation of CPR and one shock for VF, this rhythm is present on the next rhythm check. A second
shock is given and chest compressions are immediately resumed. An IV is in place and no drugs have been
given. Bag-mask ventilations are producing visible chest rise. What is your next order?
a. administer 3 sequential (stacked) shocks at 200J (biphasic defibrillator)
b. administer 3 sequential (stacked) shocks at 360J (monophasic defibrillator)
c. prepare to give amiodarone 300 mg IV
d. prepare to give epinephrine 1 mg IV
e. perform endotracheal intubation; administer 100 % oxygen
45.
You are evaluating a patient with a 15-minute duration of chest pain during transportation to the emergency
department. He is receiving oxygen, and 2 sublingual nitroglycerin tablets have relieved his chest discomfort.
He has no complaints but appears anxious. BP is 130/70 mm Hg. You observe the above rhythm on the
monitor and your next action is:
a. start epinephrine 2 to 10 ụg/kg per minute and titrate
b. administer nitroglycerine 0.4 mg SL
c. continue monitoring patient, prepare for TCP
d. initiate transcutaneous pacing (TCP)
e. give atropine 0.5 mg IV
10. 46
You arrive on-scene and find a 56 year-old diabetic woman complaining of chest discomfort. She is pale and
diaphoretic, complaining of lightheadedness. Her BP is 80/60 mm Hg. The cardiac monitor documents the
rhythm above. She is receiving oxygen at 4 L/min by Nasal Cannula, and an IV has been established.
Transcutaneous Pacing has been requested but is not yet available. Your next order is:
a. start dopamine 2 to 10 ụg/kg per minute
b. give morphine sulfate 4 mg IV
c. give atropine 1 mg IV
d. give nitroglycerine 0.4 mg SL
e. give atropine 0.5 mg IV
47.
The patient was admitted to the general medical unit with a history of alcoholism. A is in progress and he has
recurrent episodes of this rhythm. You review his chart. Notes about the 12-lead ECG say that his baseline
QT-interval is top normal to slightly prolonged. He has received 2 doses of epinephrine 1 mg and 1 dose of
amiodarone 300 mg IV so far. For his next medication you would now order:
a. give sodium bicarb 50 mEq IV
b. give magnesium sulfate 1 to 2 g IV diluted in 10 mL D5W given over 10 -20 mins.
c. repeat amiodarone 300 mg IV
d. repeat amiodarone 150 mg IV
e. lidocaine 1 to 1.5 mg IV and start infusion 2 mg/minute
11. 48
A patient becomes unresponsive and you are uncertain if a faint pulse is present with the above rhythm. Your
next action is:
a. consider causes for pulseless electrical activity.
b. Start an IV and give atropine 1 mg
c. Start an IV and give epinephrine 1 mg IV
d. Order transcutaneous pacing
e. Begin CPR with high-quality chest compressions
49.
You are monitoring a patient. Chest discomfort has been relieved with sublingual nitro and morphine sulfate 4
mg IV. He suddenly has the above persistent rhythm. You ask about symptoms and he reports mild
palpitations, but otherwise he is clinically stable with unchanged vital signs. Your next action is:
a. give immediate synchronized cardioversion
b. administer amiodarone 150 mg over 10 minutes; seek expert consultation
c. give sedation and perform synchronized cardioversion
d. give immediate unsynchronized defibrillation shock
e. administer magnesium sulfate 1 to 2 g IV diluted in 10 mL D5W over 5-20 minutes
12. 50.
A patient with an acute MI on a 12-lead ECG transmitted by the paramedics has the above findings on a rhythm
strip when a monitor is placed in the ED. The patient had resolution of moderate (5/10) chest pain with three
doses of sublingual nitroglycerine. BP is 104/70 mm Hg. Which intervention below is most important,
reducing in-hospital and 30-day mortality?
a. atropine 0.5 mg IV, total dose 2 mg as needed
b. atropine 1 mg IV, total dose 3 mg as needed
c. reperfusion therapy
d. intravenous nitroglycerin for 24 hours
e. Temporary pacing
51.
You are the code team leader and arrive finding the above rhythm with CPR in progress. Team members report
that the patient was well but complained of chest pain and collapsed. She has no pulse or respirations. Bag-
mask ventilations are producing visible chest rise, high-quality CPR is in progress, and an IV has been
established. Your next order would be:
a. administer epinephrine 1 mg
b. perform endotracheal intubation
c. administer amiodarone 300 mg
d. administer atropine 1 mg
e. start dopamine at 2 to 10 ụg/kg per minute
13. 52..
A 45 year-old woman with a history of palpitations develops lightheadedness and palpitations. She has
received adenosine 6 mg IV for the rhythm shown above without conversion of the rhythm. She is now
extremely apprehensive. BP is 108/70 mm Hg. The next appropriate intervention is:
a. repeat adenosine 3 mg IV
b. sedate and synchronized cardiovert
c. repeat adenosine 12 mg IV
d. perform vagal maneuvers and repeat adenosine 6 mg IV.
e. Perform immediate unsynchronized defibrillation
53.
A patient was in refractory VFib. A third shock has just been administered. Your immediate next order is:
a. give atropine 1 mg IV
b. give amiodarone 300 mg IV
c. give epinephrine 1 mg IV
d. resume high-quality chest compressions
e. perform endotracheal intubation
14. 54.
A 35 year-old woman presents the ED with a chief complaint of palpitations. She has no chest discomfort,
shortness of breath, or lightheadedness. Which of the following is indicated first?
a. give adenosine 3 mg IV fast
b. give adenosine 12 mg IV slow push (over 1-2 mins)
c. perform vagal maneuvers
d. give metoprolol 5 mg IV and repeat if necessary
55.
Following resuscitation with CPR and a single shock, you observe this rhythm while preparing the patient for
transport. Your patient is stable and BP is 120/80 mm Hg. She is apprehensive but has no complaints other
than palpitations. At this time you would:
a. give amiodarone 300 mg IV, start infusion
b. give magnesium sulfate 1-2 g over 20 minutes
c. give lidocaine 1-1.5 mg IV, start lidocaine infusion
d. seek expert consultation
15. 56.
You are monitoring a patient with chest discomfort who becomes suddenly unresponsive. You observe the
above rhythm on the cardiac monitor. A monophasic defibrillator is present. What is your first action:
a. give a single shock with 200 J
b. give a single shock with 360 J
c. intubate the patient and give epinephrine 2-4 mg via ET tube.
d. Begin CPR with chest compressions for 2 mins or about 5 cycles.
e. Establish an IV and give epinephrine 1 mg IV
57.
This patient suddenly collapsed and is poorly responsive. The patient has a weak carotid pulse. A cardiac
monitor, oxygen, and an IV line have been initiated. The code cart with all drugs and TCP is immediately
available. Next you would:
a. begin TCP
b. initiate dopamine 2 to 10 ụg/kg per minute and titrate heart rate
c. initiate dopamine 10 to 20 ụg/kg per minute and titrate heart rate
d. initiate epinephrine 2 to 10 ụg per minute and titrate heart rate
e. give atropine 1 mg IV up to a total dose of 3 mg.
16. 58.
This patient has been resuscitated from cardiac arrest. During the resuscitation amiodarone 300 mg was
administered. Now the patient develops severe chest discomfort, is diaphoretic, and has the above rhythm. BP
is 80/60 mm Hg. What is the next indicated action:
a. repeat amiodarone 300 mg IV.
b. Perform synchronized cardioversion
c. Give immediate unsynchronized defibrillation
d. Give lidocaine 1-1.5 mg/kg IV
e. Repeat amiodarone 150 mg IV
59.
A patient has been resuscitated from cardiac arrest and is being prepared for transport. She is intubated and is
receiving 100% oxygen. During the resuscitation she received 2 doses of epinephrine 1 mg, atropine 1 mg, and
lidocaine 100 mg IV. You now observe the above rhythm on the cardiac monitor. The rhythm abnormally is
becoming more frequent and increasing in number. You should order:
a. give amiodarone 150 mg IV, start infusion
b. give amiodarone 300 mg IV, start infusion
c. give lidocaine 1- 1.5 mg IV
d. repeat epinephrine 1 mg IV
e. give lidocaine 0.5-0.75 mg/kg IV, start lidocaine infusion
17. 60.
A patient in the ED develops recurrent chest discomfort (8/10) suspicious for ischemia. His monitored rhythm
becomes irregular as seen above. Oxygen is being administered by NC at 4 L/min and an IV line is patent. Bp
is 160/96. There are no allergies or contraindications to any meds. You would first order:
a. lidocaine 1 mg/kg and infusion 2 mg/min
b. IV nitroglycerine initiated at 10 ụg/min and titrated
c. Morphine sulfate 2-4 mg IV
d. Amiodarone 150 mg IV
e. Nitroglycerin 0.4 mg SL
61.
A patient presents with the above rhythm complaining of an irregular heart beat. She has no other complaints.
Past medical history is significant for an MI 7 years ago. BP is 110/70. At this time you would:
a. perform elective synchronized cardioversion with presedation
b. administer lidocaine 1 mg/kg IV
c. administer nitroglycerine 0.4 mg sublinqual or spray
d. continue monitoring and seek expert consultation
e. perform emergency synchronized cardioversion
18. American Heart Association ACLS Pre-Course Self Assessment Answer Sheet Dec., 2006
ECG Analysis
1_______________________________
2_______________________________
3_______________________________
4_______________________________
5_______________________________
6_______________________________
7_______________________________
8_______________________________
9_______________________________
10._______________________________
Pharmacology Practical Application
11. ________________________________________
12. ________________________________________
13. ________________________________________
14. ________________________________________
15. ________________________________________
16. ________________________________________
17. ________________________________________
18. ________________________________________
19. ________________________________________
20. ________________________________________
21. a. b. c. d.
22. a. b. c. d.
23. a. b. c. d.
24. a. b. c. d.
25. a. b. c. d.
26. a. b. c. d.
27. a. b. c. d.
28. a. b. c. d.
29. a. b. c. d.
30. a. b. c. d.
31. a. b. c. d.
32. a. b. c. d.
33. a. b. c. d.
34. a. b. c. d. e.
35. a. b. c. d. e.
36. a. b. c. d.
37. a. b. c. d.
38. a. b. c. d. e.
39. a. b. c. d.
40. a. b. c. d.
41. a. b. c. d.
42. a. b. c. d. e.
43. a. b. c. d. e.
44. a. b. c. d. e.
45. a. b. c. d. e.
46. a. b. c. d. e.
47. a. b. c. d. e.
48. a. b. c. d. e.
49. a. b. c. d. e.
50. a. b. c. d. e.
51. a. b. c. d. e.
52. a. b. c. d. e.
53. a. b. c. d. e.
54. a. b. c. d.
55. a. b. c. d.
56. a. b. c. d. e.
57. a. b. c. d. e.
58. a. b. c. d. e.
59. a. b. c. d. e.
60. a. b. c. d. e.
61. a. b. c. d. e.
19. American Heart Association ACLS Pre-Course Self Assessment Answer Key Dec., 2006
ECG Analysis
1 Supraventricular Tachycardia SVT
2 Fine Ventricular Fibrillation
3 2nd
degree Type II Block
4 NSR
5 SVT
6 Asystole
7 Polymorphic VTach
8 SVT
9 Sinus Brady
10. 2nd
degree Type II Block
Pharmacology Practical Application
11. Sinus Tachycardia
12. 3rd
degree Block
13. 2nd
degree Type I Block
14. Sinus Brady
15. Atrial Flutter
16. Coarse VFib
17. Monomorphic VTach
18. 3rd
degree Block
19 Atrial Fibrillation
20. Fine VFib
21. a. b. c. d.
22. a. b. c. d.
23. a. b. c. d.
24. a. b. c. d.
25. a. b. c. d.
26. a. b. c. d.
27. a. b. c. d.
28. a. b. c. d.
29. a. b. c. d.
30. a. b. c. d.
31. a. b. c. d.
32. a. b. c. d.
33. a. b. c. d.
34. a. b. c. d. e.
35. a. b. c. d. e.
36. a. b. c. d.
37. a. b. c. d.
38. a. b. c. d. e.
39. a. b. c. d.
40. a. b. c. d.
41. a. b. c. d.
42. a. b. c. d. e.
43. a. b. c. d. e.
44. a. b. c. d. e.
45. a. b. c. d. e.
46. a. b. c. d. e.
47. a. b. c. d. e.
48. a. b. c. d. e.
49. a. b. c. d. e.
50. a. b. c. d. e.
51. a. b. c. d. e.
52. a. b. c. d. e.
53. a. b. c. d. e.
54. a. b. c. d.
55. a. b. c. d.
56. a. b. c. d. e.
57. a. b. c. d. e.
58. a. b. c. d. e.
59. a. b. c. d. e.
60. a. b. c. d. e.
61. a. b. c. d. e.